Population pharmacokinetics and optimized dosing of piperacillin-tazobactam in hematological patients with febrile neutropenia.

ABSTRACT: Hematological patients with febrile neutropenia receiving piperacillin-tazobactam may experience pharmacokinetic alterations that compromise drug exposure. We aimed to characterize the population pharmacokinetics of piperacillin in plasma and provide optimized dosing recommendations for this patient population. A population pharmacokinetic analysis was conducted in patients who received piperacillin-tazobactam as part of the BEATLE study, which compared the efficacy, safety, and pharmacokinetic/pharmacodynamic target attainment of β-lactams administered in extended infusion versus short 30 min infusion in adult hematological patients with febrile neutropenia. Monte Carlo simulations were performed to evaluate, for each dosing regimen, the probability of attaining (i) an efficacy target of

SUBMITTER: Laporte-Amargos J 

PROVIDER: S-EPMC12777563 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature